Caterpillar bids for Australia’s RPMGlobal- AFR
Chicago Atlantic Group, LP, along with its affiliates, recently acquired a significant number of shares in Vireo Growth Inc. (NASDAQ:VREO), a company currently valued at $161 million. According to InvestingPro data, the company has shown strong revenue growth of 13% in the last twelve months. According to a recent SEC filing, the group purchased a total of 87,500 subordinate voting shares in two separate transactions. The purchases, made on March 28 and March 31, 2025, amounted to a total value of $37,520.
The shares were acquired at prices ranging from $0.4255 to $0.4437 per share. Following these transactions, Chicago Atlantic Group and its affiliates now hold a total of 486,772 shares in Vireo Growth. These transactions highlight the group’s continued interest and investment in the pharmaceutical preparations sector, where Vireo Growth is actively engaged. InvestingPro analysis shows the company maintains a "GREAT" overall financial health score, despite operating with a moderate debt-to-equity ratio of 1.62.
The reporting entities, including Chicago Atlantic Credit Opportunities, LLC and Chicago Atlantic Advisers, LLC, are significant stakeholders, each owning over ten percent of the company’s shares. The acquisitions were executed by Peter Sack, an authorized person representing all filers in this transaction. According to InvestingPro, the company’s current Fair Value indicates it is fairly valued, with additional insights available in the comprehensive Pro Research Report.
In other recent news, Vireo Growth Inc. reported a 15.4% increase in full-year revenue, reaching $99.4 million, with fourth-quarter revenue up 3.5% to $25 million. Despite these gains, the company announced a fourth-quarter net loss of $15.7 million due to one-time transaction expenses. Vireo Growth is planning significant expansions, including a new cultivation facility in Minnesota and the launch of adult-use sales in the state, indicating a transformative year ahead. The company maintains a strong cash position of $91.6 million, which supports its growth initiatives. Analysts have noted the company’s strategic focus on mergers and capital deployment, with expectations of significant contributions from its New York facility by the second quarter of 2025. The firm also plans to divest a portion of its New York assets while enhancing its production of premium flowers. Vireo Growth’s ongoing merger transactions are expected to close in 2025, pending regulatory and shareholder approvals. These developments underscore the company’s efforts to expand its market presence and operational capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.